阿达木单抗生物类似药(Momenta Pharmaceuticals, Inc.)(Adalimumab biosimilar(Momenta Pharmaceuticals, Inc.))

概要

基本信息

药物类型

生物类似药、单克隆抗体

别名

Adalimumab biosimilar、BAX 923、BAX-2923

+ [3]

靶点

TNF-α

作用机制

TNF-α抑制剂(肿瘤坏死因子α抑制剂)

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病其他疾病

在研适应症-

非在研适应症

炎症斑块状银屑病类风湿关节炎

原研机构

Momenta Pharmaceuticals, Inc.

在研机构-

非在研机构

Momenta Pharmaceuticals, Inc.Shire Pharmaceuticals Services Ltd.

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 26792L

当前序列信息引自: *****

Sequence Code 88699H

当前序列信息引自: *****

关联

8

项与阿达木单抗生物类似药(Momenta Pharmaceuticals, Inc.) 相关的临床试验

NCT06180382 / Recruiting临床4期IIT

Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration: A Randomized, Multicentre, Controlled Trial

A substantial fraction of IBD patients with an initial response to infliximab or adalimumab later experience re-emerging active disease despite ongoing anti-Tumour Necrosis Factor (TNF) agents maintenance therapy. The optimal intervention in patients with secondary loss-of-response (LOR) is still poorly defined, as there are still scant data on how best to choose the next intervention from among dose-intensification, switch to another anti-TNF or switch out of the anti-TNF class. Moreover, according to STRIDE 2 recommendations and CALM study, optimize patients based solely on lack of biological remission (CRP, calprotectin) can be discuss. If CALM study has showed that the intervention arm based on regular monitoring fecal calprotectin, CRP and/or CDAI to optimize patients under adalimumab was significantly associated to an increase rate of mucosal healing that the standard of care strategy based on only clinical activity, TDM was not available to guide drug optimization strategy.

开始日期2024-10-31

申办/合作机构

Centre Hospitalier Universitaire de Saint-Etienne

[+1]

NCT02878083 / TerminatedN/AIIT

Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)

The main objective of this project is to demonstrate the feasability of an endomicroscopic biomarker of efficacy of vedolizumab and adalimumab, in Ulcerative colitis (UC) by coupling vedolizumab to a fluorescent component, FITC (Fluorescein isothiocyanate) , and adalimumab to rhodamine.
This project should allow the development of a biomarker of therapeutic efficacy for vedolizumab and adalimumab that can be used in a single time-frame in vivo in humans, while respecting manufacturing standards and Good manufacturing procedures.

开始日期2017-01-11

申办/合作机构

Nantes University Hospital

[+3]

NCT02722044 / Completed临床3期

An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)

The purpose of this study is to evaluate the usability of an auto-injector (AI) for the delivery of M923 in patients with rheumatoid arthritis (RA)

开始日期2016-04-01

申办/合作机构

Momenta Pharmaceuticals, Inc.

100 项与阿达木单抗生物类似药(Momenta Pharmaceuticals, Inc.) 相关的临床结果

登录后查看更多信息

100 项与阿达木单抗生物类似药(Momenta Pharmaceuticals, Inc.) 相关的转化医学

登录后查看更多信息

100 项与阿达木单抗生物类似药(Momenta Pharmaceuticals, Inc.) 相关的专利（医药）

登录后查看更多信息

4

项与阿达木单抗生物类似药(Momenta Pharmaceuticals, Inc.) 相关的文献（医药）

2023-01-01·Frontiers in pharmacology

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study.

Article

作者: Zhou, He ; Liang, Jie ; Wang, Fang ; Li, Xiaofei ; Yang, Gang ; Shi, Yanting ; Li, Ruixia ; Wu, Tong

Objective: Adalimumab (ADA) is an effective treatment for inflammatory bowel disease (IBD), both ulcerative colitis (UC) and Crohn's disease (CD). The equal effect between the original ADA and biosimilars from Europe and the United States has been shown. However, the biosimilar of ADA is different in China. The effectiveness and safety data of ADA biosimilar (HS016) in China have yet to be discovered. Patients and methods: 91 patients (75 CD, 16 UC) received HS016 treatment and were enrolled in this study. Therapeutic response and safety profiles were analyzed. Therapeutic drug monitoring (TDM) was also carried out among nonresponse patients. After being considered as "nonresponse" (after three or 6 months of treatment), 20 patients' serum TNFα concentrations were measured and correlated to their disease severity. Results: Among active CD patients (n = 61), 75.4% (46/61) at 12 w, 73.8% (45/61) at 26 w, 50.8% (31/61) at 52 w achieved the clinical response, respectively; 55.7% (34/61) at 12 w, 65.6% (40/61) at 26 w, and 45.9% (28/61) at 52 w achieved clinical remission. The maintained remission rates of CD (n = 14) in clinical remission were 100% (14/14) at 12 w, 78.6% (11/14) at 26 w, and 63.6% (7/11) at 52 w, respectively. Among active UC patients, 37.5% (6/16) at 12 w and 50% (8/16) at 26 w achieved clinical response. Total adverse event rates were 5.5% (5/91) during 52-week visits. Due to the inadequate serum drug concentration, 30.4% (7/23) of patients had poor clinical responses. Elevations of serum anti-drug antibodies occurred in one additional patient (4.3%). Conclusion: ADA biosimilar HS016 had good efficacy and safety in Chinese IBD patients.

2020-06-01·BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial

Article

作者: Jiang, Lindi ; Li, Jingyang ; Li, Fen ; Wu, Huaxiang ; Wei, Wei ; Li, Tianwang ; Dong, Lingli ; Li, Mengtao ; He, Lan ; Zeng, Xiaofeng ; Zuo, Xiaoxia ; Wan, Weiguo ; Liu, Huaxiang ; Xu, Jian ; He, Dongyi ; Su, Jinmei ; Liu, Xiangyuan ; Wang, Yanyan ; Chen, Haiying ; Xu, Jianhua ; Lu, Xin ; Liu, Yi ; Li, Xiaofeng ; Zhao, Dongbao ; Tao, Yi ; Zhang, Zhiyi ; Huang, Anbin ; Huang, Cibo ; Zhang, Zhuoli ; Liu, Xiumei

OBJECTIVE:

The aim of this study was to evaluate the efficacy and safety of the biosimilar candidate of adalimumab (HS016) compared with adalimumab (Humira) for the treatment of active ankylosing spondylitis.

METHODS:

A multicenter, randomized, double-blind, parallel, positive control, phase III clinical trial was conducted at 28 locations in China. Patients with active ankylosing spondylitis were randomized in a 2:1 ratio to subcutaneously receive 40 mg of either HS016 or adalimumab every other week for 24 weeks. The primary endpoint was to achieve at least a 20% improvement (ASAS20) in patients at 24 weeks according to the Assessment of Spondyloarthritis International Society criteria. The secondary endpoint included other efficacy assessment parameters, health evaluations, safety, pharmacokinetic, and immunogenicity parameters.

RESULTS:

Following the random assignment of 648 patients into HS016 (n = 416) and adalimumab (n = 232) groups, no significant difference was found in the ASAS20 response rates at 24 weeks between the HS016 (364/416, 87.5%) and adalimumab (209/232, 90.1%) treatments and the difference between the response rates (- 2.59%; 90% confidence interval [CI] - 6.77 to 1.60) was within the predefined equivalence margin (± 15%). There were also no significant differences when the secondary endpoints were compared (all p > 0.05). Similarly, the rates of treatment-emergent adverse events (TEAEs) were not significantly different between the two groups, with most TEAEs being mild to moderate. Only nine severe cases were found, including seven within the HS016 group, three (0.7%) of which were tuberculosis cases. Plasma concentrations of HS016 and adalimumab from weeks 12 to 14 were similar during the steady-state period and steady-state maximal concentration (C_max,ss) was equivalent for HS016 (7356.6 ng/mL) and adalimumab (7600.3 ng/mL). The accumulated proportion of patients with positive human anti-human antibodies (HAHAs) at week 24 was 326/412 (79.1%) in the HS016 group and 183/229 (79.9%) in the adalimumab group (p > 0.05), while the accumulated proportion of patients with positive neutralizing antibody (NAb) tests were 72/412 (17.5%) in the HS016 group and 43/229 (18.8%) in the adalimumab group (p > 0.05).

CONCLUSION:

HS016 resembled adalimumab in efficacy and safety over the 24-week treatment period.

TRIAL REGISTRATION NUMBER:

ChiCTR1900022520.

2018-02-01·Pharmacology research & perspectives4区 · 医学

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects

4区 · 医学

ArticleOA

作者: Darne, Siddhesh ; Weilert, Doris ; Pavlova, Borislava G. ; Rosano, Molly ; Doralt, Jennifer ; Hillson, Jan ; Goel, Niti ; Caminis, John ; Chance, Kamali ; Alai‐Safar, Mehrshid ; Reeve, Russell ; Roach, James ; Huntenburg, Carolyn ; Mant, Tim ; Rhyne, Paul W. ; Ganguly, Tanmoy ; Palmer, Donna

Abstract:

The aims of this randomized, double‐blind, three‐arm, single‐dose study were to demonstrate pharmacokinetic (PK) equivalence of the adalimumab biosimilar M923 (hereafter referred to as “M923”) to each of 2 reference products, and to assess M923's safety and immunogenicity. Primary PK endpoints were maximum observed concentration (Cmax), area under the curve (AUC) from time 0 extrapolated to infinity (AUC0‐inf), and AUC from time 0 to 336 hours (AUC0‐336). Secondary endpoints included safety and immunogenicity assessments. Healthy subjects were randomized 1:1:1 to receive a 40‐mg dose of M923 (n = 107); adalimumab US Humira (n = 105), hereafter referred to as “US Humira”; or adalimumab EU Humira (n = 103), hereafter referred to as “EU Humira.” PK equivalence was demonstrated for all primary PK endpoints. Geometric least squares means ratios (GMRs) for Cmax, AUC0‐inf, and AUC0‐336 were 99.4, 100.9, and 100.5, respectively, between the M923 and EU Humira arms and 102.6, 104.2, and 102.9 between the M923 and US Humira arms. The 90% confidence intervals of the GMRs for all PK endpoints were within prespecified confidence bounds of 80%‐125%. Adverse event rates were similar across the M923 (47.7%), US Humira (50.9%), and EU Humira (53.3%) arms and were generally mild (73.7%) or moderate (22.0%). The proportion of subjects with a confirmed antidrug antibody (ADA) response was similar across study arms. This study demonstrated bioequivalent PK among M923, US Humira, and EU Humira and demonstrated that the PK parameters were consistent with similar safety and tolerability profile and ADA response rates.

1

项与阿达木单抗生物类似药(Momenta Pharmaceuticals, Inc.) 相关的新闻（医药）

2016-09-28

·Pharma Times

Shire steps away from biosimilars

Shire has handed back rights to the two biosimilars it acquired through its recent purchase of Baxalta, retaining its focus on the development of drugs for rare diseases. The UK-based group is returning global development and commercialisation rights to M923, a proposed biosimilar of Humira (adalimumab), to US group Momenta Pharmaceuticals, but will continue to fund the programme for 12 months as per the original deal with Baxalta. "We view Shire's decision as a significant opportunity for us to capture additional value from this program for the Company and its shareholders. We remain very excited about the potential for our biosimilar HUMIRA candidate and look forward to reporting top-line results of the current Phase III trial of M923 in late 2016," said Momenta's president and chief executive, commenting on the move. US biotech Coherus BioSciences has also regained from Shire all development and commercial rights previously licensed for CHS-0214 etanercept, a biosimilar candidate to Enbrel, for Europe, Canada, Brazil, the Middle East and other territories. The drug has successfully completed two Phase III studies, in chronic plaque psoriasis and rheumatoid arthritis, data from which will support its European marketing application, planned for the fourth quarter of this year. "These reacquired geographical rights fit well with our existing US CHS-0214 rights, and we now have the opportunity to license throughout Europe, US and other key commercial geographies two complimentary Anti-TNF assets - CHS-0214, an Enbrel biosimilar candidate and CHS-1420, a Humira biosimilar candidate".

生物类似药

100 项与阿达木单抗生物类似药(Momenta Pharmaceuticals, Inc.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L04AB04	DB00051

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
类风湿关节炎	临床3期	美国	Momenta Pharmaceuticals, Inc.	2016-04-01
斑块状银屑病	临床3期	美国	Momenta Pharmaceuticals, Inc.	2015-09-01
斑块状银屑病	临床3期	保加利亚	Momenta Pharmaceuticals, Inc.	2015-09-01
斑块状银屑病	临床3期	加拿大	Momenta Pharmaceuticals, Inc.	2015-09-01
斑块状银屑病	临床3期	捷克	Momenta Pharmaceuticals, Inc.	2015-09-01
斑块状银屑病	临床3期	爱沙尼亚	Momenta Pharmaceuticals, Inc.	2015-09-01
斑块状银屑病	临床3期	德国	Momenta Pharmaceuticals, Inc.	2015-09-01
斑块状银屑病	临床3期	拉脱维亚	Momenta Pharmaceuticals, Inc.	2015-09-01
斑块状银屑病	临床3期	波兰	Momenta Pharmaceuticals, Inc.	2015-09-01
斑块状银屑病	临床3期	斯洛伐克	Momenta Pharmaceuticals, Inc.	2015-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


VARSITY (UEGW2020)	N/A	溃疡性结肠炎	769	Vedolizumab	糧顧繭構鏇襯遞餘淵壓(艱願獵夢鏇觸簾鑰鹽餘) = 鏇積範壓鹽憲廠鑰壓餘夢顧構築憲淵願醖構遞 (繭網窪鑰膚襯構醖淵糧 ) 更多	积极	2020-10-01
VARSITY (UEGW2020)	N/A	溃疡性结肠炎	769	Adalimumab	糧顧繭構鏇襯遞餘淵壓(艱願獵夢鏇觸簾鑰鹽餘) = 鬱簾繭衊壓醖壓積醖鹹夢顧構築憲淵願醖構遞 (繭網窪鑰膚襯構醖淵糧 ) 更多	积极	2020-10-01
NCT02722044 (CTgov)	临床3期	类风湿关节炎	33	M923	獵構範遞衊襯淵鏇範淵(衊醖構獵蓋觸選遞積襯) = 廠窪鬱憲積衊醖簾繭顧艱鹹觸蓋築壓鑰簾簾窪 (繭齋餘觸蓋夢廠鏇鏇網, 醖遞窪鹽範製艱窪糧構 ~ 網鑰獵憲觸觸網齋夢鏇) 更多	-	2018-05-01